Professor Alan Ashworth
President, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco and Senior Vice President for Clinical Services, University of California San Francisco Health, United States of America
About this event
- Date and time Fri 14 Jan 2022 from 9:10am to 3:40pm
- Location Online
- Organised by Oncology, Medical Genetics
Join us to understand how critically important the genetic and epigenetic changes in cancer are for disease biology and novel treatments.
There are 30 free bursary places available on a first come, first served basis. To claim your free place, please email us at oncology@rsm.ac.uk.
Learning objectives include:
- The role of genetic and epigenetic changes in cancer biology with examples of how this has already impacted patient treatment and survival
- Novel emerging technologies such as gene-editing and radiomics to understand how these may lead to new therapies and predictors of response, respectively
- Gain an insight into the trials and tribulations of genetic testing from a consumer point of view
This meeting will be relevant to clinical and medical oncologists, geneticists, basic scientists interested in cancer biology and genetics (cancer researchers), radiologist, pathologists, pharmacists, cancer researchers and cancer nurses, medical students and trainees interested in cancer and genetics.
A CPD certificate with CPD credit will be issued to those joining the webinar live as well as those who watch the recording afterwards. Certificates will be issued 7 days after the webinar to those who watch it live and after 30 days for those that watch the recording.
This webinar is available for on-demand viewing. The webinar recording will be available for registered delegates up to 60 days after the live webinar broadcast via Zoom. The link will be sent 24 hours after the webinar takes place.
Join in the conversation online
Follow us on Twitter: @RoySocMed
We would like to thank our sponsor GSK for their support of this meeting. Please note that the scientific programme and content has not been influenced in any way by the sponsor. GSK have received a number of delegate passes to attend the meeting as part of their contribution.
Key speakers
Professor Clare Scott
Professor of Gynaecological Cancer, University of Melbourne, Joint Head, Clinical Translation Centre, Laboratory Head, Walter and Eliza Hall Institute of Medical Research, Medical Oncologist, Peter MacCallum Cancer Centre, Royal Melbourne and Royal Women's Hospitals, Australia
Professor Ian Tomlinson
Director, Cancer Research UK Edinburgh Centre, Charles and Ethel Barr Chair of Cancer Research
Agenda
View the programme
Welcome and introduction
Session one: Genetics
Chair: Professor Michael Seckl, Immediate Past President, Oncology Section, Royal Society of Medicine and Dr Susana Banerjee, Consultant Medical Oncologist, The Royal Marsden NHS Foundation Trust and Reader in Women’s Cancers, Institute of Cancer Research
Breast cancer genetics
Professor Alan Ashworth, President, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco and Senior Vice President for Clinical Services, University of California San Francisco Health, United States of America
Ovarian cancer genetics
Professor Clare Scott, Professor of Gynaecological Cancer, University of Melbourne, Joint Head, Clinical Translation Centre, Laboratory Head, Walter and Eliza Hall Institute of Medical Research, Medical Oncologist, Peter MacCallum Cancer Centre, Royal Melbourne and Royal Women's Hospitals, Australia
PARP inhibitors in clinical practice- ovarian cancer
Dr Susana Banerjee
Tea and coffee break
Session two: Epigenetics
Chair: Professor Chrissie Thirlwell, Mireille Gillings Professor of Cancer Genomics, University of Exeter Medical School and Professor Michael Seckl
Epigenetics in cancer
Professor Idriss Bennani-Baiti, President and Chief Executive Officer, Cancer Epigenetics Society, Austria
Neuroendocrine tumours - cracking the epigenetic code
Professor Chrissie Thirlwell
Epigenetic treatment strategies for ovarian cancer
Professor Robert Brown, Senior Research Investigator, Imperial College London
Lunch
Session three: Technological advances in cancer and genetics
Chair: Professor Christopher Nutting, President, Oncology Section, Royal Society of Medicine
Leveraging the microbiome for improved cancer outcomes
Dr James Kinross, Senior Lecturer in Surgery, Imperial College London
Radiomics
Professor Eric Aboagye, Professor of Cancer Pharmacology and Molecular Imaging, Imperial College London
Allogeneic and genome edited CAR T- cell therapy: Is it ready for the clinic?
Dr Claire Roddie, Consultant Haematologist, University College London Hospitals NHS Foundation Trust, Honorary Senior Lecturer in Haematology, University College London
Tea and coffee break
Session four: Targeted genetic treatment old and new
Chair: Professor Christopher Nutting and Professor Michael Seckl
Plenary session: Colorectal cancer genetics and new targets for treatment
Professor Ian Tomlinson, Director, Cancer Research UK Edinburgh Centre, Charles and Ethel Barr Chair of Cancer Research
Close of meeting
Sponsors
Location
Online
Disclaimer: All views expressed in this webinar are of the speakers themselves and not of the RSM nor the speaker's organisations.
Registration for this webinar will close 2 hours prior to the start time. You will receive the webinar link 2 hours before the meeting. Late registrations will not be accepted.
